Disc Medicine(IRON) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update • Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all proposed study parameters with the potential for accelerated approval based on existing data • Presented proof-of-mechanism data for Phase 1b trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia at the American Society ...